Newer blood thinners, called NOACs (Novel Oral Anticoagulants), may help slow cognitive decline in people with both Alzheimer’s disease and atrial fibrillation, according to a recent study published in the European Heart Journal. Atrial fibrillation is a heart rhythm disorder that increases the risk of stroke, while Alzheimer’s is a progressive brain disease that affects memory and thinking. Researchers from Karolinska Institutet in Sweden analyzed data from 7,308 people diagnosed with both conditions and divided them into three groups: those taking NOACs, those on the older blood thinner warfarin, and those not taking anticoagulant medication. The study found that those on NOACs showed a slower decline in cognitive function over time, as measured by the Mini-Mental State Examination (MMSE), compared to those on warfarin or no medication. The difference was about 0.2 MMSE points per year, which the researchers suggest could add up to a noticeable effect over time. The benefits of NOACs extended beyond cognitive function. Patients on NOACs had lower risks of death, stroke, blood clots, and fractures compared to those who didn’t receive anticoagulants. Warfarin also reduced the risks of death, stroke, and blood clots, but it was associated with a higher risk of major bleeding. The researchers note that the study was observational, meaning it tracked real-world outcomes without directly testing the drugs. This type of study cannot prove that NOACs caused the observed benefits, as other factors that influence both treatment choices and health outcomes could not be fully controlled. Additionally, some participants may have switched medications during the study period, which could affect the results. The study was funded by several organizations, including the Swedish Research Council and the Swedish Brain Foundation. Maria Eriksdotter, a professor at Karolinska Institutet and senior consultant in geriatric medicine, led the study and has participated in meetings with pharmaceutical companies. The researchers suggest that NOACs may improve cognition by improving blood flow to the brain and reducing small-scale brain damage. However, they caution that further research is needed to confirm these findings and better understand the long-term effects of NOACs in this patient group.